Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hairy cell leukemia. Current management.

L L Doane1, M J Ratain, H M Golomb

  • 1Section of Hematology/Oncology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois.

Hematology/Oncology Clinics of North America
|April 1, 1990
PubMed
Summary

New therapies like pentostatin and alpha-interferon have significantly improved the long-term outlook for Hairy Cell Leukemia (HCL) patients. Pentostatin offers a potential cure, while alpha-interferon is a primary treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late Relapse in Hodgkin's Disease: Report of Five Cases and a Review of the Literature.

Leukemia & lymphoma·2016
Same author

Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

Leukemia & lymphoma·2016
Same author

Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

Leukemia & lymphoma·2016
Same author

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.

Leukemia & lymphoma·2016
Same author

HDS: Establishment of a New Cell Line from a Hairy Cell Leukemia Patient with Resistance to Alpha-Interferon Therapy.

Leukemia & lymphoma·2016
Same author

The Treatment of Hairy Cell Leukemia: A Review.

Leukemia & lymphoma·2016

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Hairy Cell Leukemia (HCL) is a rare B-cell leukemia.
  • Historically, treatment options for HCL were limited, leading to poorer long-term prognoses.

Purpose of the Study:

  • To review the recent advancements in systemic therapies for Hairy Cell Leukemia.
  • To evaluate the efficacy and role of pentostatin and alpha-interferon in HCL management.

Main Methods:

  • Review of current literature and clinical data on HCL treatment outcomes.
  • Analysis of response rates, remission durations, and survival data for key therapies.

Main Results:

  • Pentostatin demonstrates high complete response rates (over 75%) and potential for cure in HCL.

Related Experiment Videos

  • Alpha-interferon serves as a primary systemic therapy and can be used for re-induction of remission.
  • Splenectomy remains a valuable first-line option for select HCL patients, offering long remissions.

    • Conclusions:

    • The long-term outlook for HCL patients has markedly improved due to novel systemic therapies.
    • Pentostatin and alpha-interferon represent significant progress in HCL treatment, offering hope for durable remissions and potential cures.